Lundbeck
HLUYYNext catalyst
Eptinezumab
Chronic Migraine in Children
Get an email about HLUYY's next catalysts
Track Lundbeck (HLUYY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 0 past
Eptinezumab Phase 3 Est. Readout (PROSPECT-1)
Primary completion for Eptinezumab trial (NCT05897320) in Episodic Migraine
SourceLu AG13909 Phase 2 Est. Readout (BalanCeD)
Estimated primary completion for Lu AG13909 trial (NCT06471829) in Cushing's Disease. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Nalmefene
Alcohol Dependence
Idalopirdine
Alzheimer's Disease
Vortioxetine
Depressive Disorder, Major
Lu AF35700
Schizophrenia
Clobazam Low Dose
Epilepsy
Lu AA21004
Generalized Anxiety Disorder
Venlafaxine extended release
Major Depressive Disorder
MK0928, gaboxadol/Duration of Treatment - 1 year
Insomnia
Azilect®
Parkinson's Disease
Bendamustine at a
Indolent Non-Hodgkin's Lymphoma
Agomelatine
Major Depressive Disorder
Escitalopram
Major Depressive Disorder
Bupropion XL
Depression
Clobazam High Dose
Epilepsy
Lu AF82422
Multiple System Atrophy
Desmoteplase
Acute Ischemic Stroke
Adjunct brexpiprazole
Major Depression Disorder
ADT
Major Depressive Disorder
Sertindole
Schizophrenia
Intravenous Carbamazepine (IV CBZ)
Epilepsy
Brexpiprazole
Schizophrenia
MK0928, gaboxadol
Insomnia
Vortioxetine (Lu AA21004)
Major Depressive Disorder
Clobazam Medium Dose
Epilepsy
Clobazam
Lennox-Gastaut Syndrome
gaboxadol
Insomnia
rasagiline
Parkinson's Disease
Eptinezumab
Chronic Migraine in Children
Zicronapine
Schizophrenia
Lu AG09222
Migraine
Bifeprunox
Bipolar I Disorder
Lu AE58054
Schizophrenia
Lu AG13909
Congenital Adrenal Hyperplasia
Lu AA24493
Friedreich's Ataxia
Venlafaxine XL
Major Depressive Disorder
Methylprednisoloneacetate
Knee Joint Osteoarthrosis
Erythropoietin
Bipolar Disorder
Melperone HCl
Parkinson's Disease
Vortioxetine (tablet)
Depressive Disorder, Major
Zicronapine open-label lead-in
Schizophrenia
Vortioxetine (IV)
Depressive Disorder, Major
Lu AA24530
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nalmefene | Phase 3 | Alcohol Dependence | - | - |
Idalopirdine | Phase 3 | Alzheimer's Disease | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
Lu AF35700 | Phase 3 | Schizophrenia | - | - |
Clobazam Low Dose | Phase 3 | Epilepsy | - | - |
Lu AA21004 | Phase 3 | Generalized Anxiety Disorder | - | - |
Venlafaxine extended release | Phase 3 | Major Depressive Disorder | - | - |
MK0928, gaboxadol/Duration of Treatment - 1 year | Phase 3 | Insomnia | - | - |
Azilect® | Phase 3 | Parkinson's Disease | - | - |
Bendamustine at a | Phase 3 | Indolent Non-Hodgkin's Lymphoma | - | - |
Agomelatine | Phase 3 | Major Depressive Disorder | - | - |
Escitalopram | Phase 3 | Major Depressive Disorder | - | - |
Bupropion XL | Phase 3 | Depression | - | - |
Clobazam High Dose | Phase 3 | Epilepsy | - | - |
Lu AF82422 | Phase 3 | Multiple System Atrophy | - | - |
Desmoteplase | Phase 3 | Acute Ischemic Stroke | - | - |
Adjunct brexpiprazole | Phase 3 | Major Depression Disorder | - | - |
ADT | Phase 3 | Major Depressive Disorder | - | - |
Sertindole | Phase 3 | Schizophrenia | - | - |
Intravenous Carbamazepine (IV CBZ) | Phase 3 | Epilepsy | - | - |
Brexpiprazole | Phase 3 | Schizophrenia | - | - |
MK0928, gaboxadol | Phase 3 | Insomnia | - | - |
Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder | - | - |
Clobazam Medium Dose | Phase 3 | Epilepsy | - | - |
Clobazam | Phase 3 | Lennox-Gastaut Syndrome | - | - |
gaboxadol | Phase 3 | Insomnia | - | - |
rasagiline | Phase 3 | Parkinson's Disease | - | - |
Eptinezumab | Phase 3 | Chronic Migraine in Children | - | - |
Zicronapine | Phase 3 | Schizophrenia | - | - |
Lu AG09222 | Phase 2 | Migraine | - | - |
Bifeprunox | Phase 2 | Bipolar I Disorder | - | - |
Lu AE58054 | Phase 2 | Schizophrenia | - | - |
Lu AG13909 | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
Lu AA24493 | Phase 2 | Friedreich's Ataxia | - | - |
Venlafaxine XL | Phase 2 | Major Depressive Disorder | - | - |
Methylprednisoloneacetate | Phase 2 | Knee Joint Osteoarthrosis | - | - |
Erythropoietin | Phase 2 | Bipolar Disorder | - | - |
Melperone HCl | Phase 2 | Parkinson's Disease | - | - |
Vortioxetine (tablet) | Phase 2 | Depressive Disorder, Major | - | - |
Zicronapine open-label lead-in | Phase 2 | Schizophrenia | - | - |
Vortioxetine (IV) | Phase 2 | Depressive Disorder, Major | - | - |
Lu AA24530 | Phase 2 | Major Depressive Disorder | - | - |
epilepsy
1 drug in this indication
migraine prevention
1 drug in this indication
endogenous Cushing's syndrome
1 drug in this indication
narcolepsy
1 drug in this indication
multiple system atrophy
1 drug in this indication
multiple system atrophy (MSA)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Lundbeck's drug pipeline?→
CatalystAlert tracks 42 drug candidates in Lundbeck's (HLUYY) pipeline across Phase 3, Phase 2. Its lead program is Eptinezumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lundbeck's next FDA catalyst?→
Lundbeck's (HLUYY) next tracked catalyst is a Phase 3 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HLUYY biotech catalysts?→
Add HLUYY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lundbeck's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
